Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 4, 2009, Pages 551-557

  Nishio, Shin ^b   Katsumata, Noriyuki ^a   Matsumoto, Koji ^a   Tanabe, Hiroshi ^a   Yonemori, Kan ^a   Kouno, Tsutomu ^a   Shimizu, Chikako ^a   Ando, Masashi ^a   Kamura, Toshiharu ^b   Kasamatsu, Takahiro ^a   Fujiwara, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Fallopian tube; Primary peritoneal cancer; Recurrent ovarian; Third line chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; MITOMYCIN; PACLITAXEL; TOPOTECAN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PERITONEUM CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CA-125 ANTIGEN; DISEASE PROGRESSION; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS;

EID: 61449123093     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-008-0488-x     Document Type: Article

References (21)

1. G Blackledge F Lawton C Redman K Kelly 1989 Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials Br J Cancer 59 650 653
2. MA Bookman 2003 Developmental chemotherapy and management of recurrent ovarian cancer J Clin Oncol 21 149s 167s
3. KA Donovan PG Greene JL Shuster EE Partridge DC Tucker 2002 Treatment preferences in recurrent ovarian cancer Gynecol Oncol 86 200 211
4. C Doyle M Crump M Pintilie AM Oza 2001 Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer J Clin Oncol 19 1266 1274
5. EA Eisenhauer JB Vermorken M van Glabbeke 1997 Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients Ann Oncol 8 963 968
6. J Engel R Eckel G Schubert-Fritschle J Kerr W Kuhn J Diebold R Kimmig J Rehbock D Holzel 2002 Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate Eur J Cancer 38 2435 2445
7. MK Findley H Lee MV Seiden MA Shah AF Fuller A Goodman RT Penson 2005 Do more lines of chemotherapy make you live longer? Treatment for ovarian cancer comparing cohorts of patients 1989-90 with 1995-6 in multivariate analysis of survival J Clin Oncol 23 Suppl 16S
8. MF Fung ME Johnston EA Eisenhauer L Elit HW Hirte B Rosen 2002 Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum-a systematic review of the evidence from randomized trials Eur J Gynaecol Oncol 23 104 110
9. RT Greenlee MB Hill-Harmon T Murray M Thun 2001 Cancer statistics CA Cancer J Clin 51 15 36
10. AP Heintz F Odicino P Maisonneuve U Beller JL Benedet WT Creasman HY Ngan M Sideri S Pecorelli 2001 Carcinoma of the ovary J Epidemiol Biostat 6 107 138
11. A Jemal T Murray A Samuels A Ghafoor E Ward MJ Thun 2003 Cancer statistics 2003 CA Cancer J Clin 53 5 26
12. M Markman 1998 ''Recurrence within 6 months of platinum- therapy'': an adequate definition of ''platinum-refractory'' ovarian cancer? Gynecol Oncol 69 91 92
13. M Markman R Rothman T Hakes B Reichman W Hoskins S Rubin W Jones L Almadrones JL Lewis Jr 1991 Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J Clin Oncol 9 389 393
14. M Markman A Kennedy K Webster B Kulp G Peterson J Belinson 1998 Evidence that a ''treatment-free interval of less than 6 months'' does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma J Cancer Res Clin Oncol 124 326 328
15. M Markman A Kennedy K Webster P Elson G Peterson B Kulp J Belinson 1999 Clinical features of hypersensitivity reactions to carboplatin J Clin Oncol 17 1141
16. RP Rocconi AS Case JM Staughn Jr JM Estes EE Partridge 2006 Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effective analysis Cancer 107 536 543
17. S Tangjitgamol HT See S Manusirvithaya CF Levenback DM Gershenson JJ Kavanagh 2004 Third-line chemotherapy in platinum-and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients Int J Gynecol Cancer 12 804 814
18. JT Thigpen RB Vance T Khansur 1993 Second-line chemotherapy for recurrent carcinoma of the ovary Cancer 71 1559 1564
19. JT Thigpen JA Blessing H Ball SJ Hummel RJ Barrett 1994 Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group Study J Clin Oncol 12 1748 1753
20. A Villa F Parazzini G Scarfone P Guarnerio G Bolis 1999 Survival and determinants of response to third-line chemotherapy in sensitive recurrent ovarian cancer patients Br J Cancer 79 373 374
21. KM Zanotti LA Rybicki AW Kennedy JL Belinson KD Webster B Kulp G Peterson M Markman 2001 Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy J Clin Oncol 19 3126 3129